EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)

Yoshiya Tanaka iD, Masafumi Kawanishi iD, Megumi Nakanishi, Hironori Yamasaki, Tsutomu Takeuchi iD

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac126 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Yoshiya Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taisho Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim is to assess the efficacy and safety of a 52-week subcutaneous ozoralizumab treatment at 30 and 80 mg without methotrexate (MTX) in active rheumatoid arthritis.

Methods

This randomised, open-label, multicentre phase III trial randomly allocated 140 patients in 2:1 ratio as subcutaneous ozoralizumab at 30 or 80 mg every 4 weeks for 52 weeks without MTX.

Results

Both groups administered ozoralizumab at 30 and 80 mg showed good clinical improvement. The American College of Rheumatology response rates were high at Week 24 and maintained through 52 weeks. The ozoralizumab groups also showed good improvement in other end points, and improvements observed from Week 1 were maintained through 52 weeks. Improvements in many efficacy assessments were similar between doses. No deaths were reported, and serious adverse events occurred in a total of 20 patients in the ozoralizumab groups. Increased antidrug antibodies were observed in approximately 40% of patients in the ozoralizumab groups, and 27.7% of the patients in the 30 mg group were neutralising antibody-positive.

Conclusions

Ozoralizumab, at 30 and 80 mg, demonstrated significant therapeutic effects without MTX, and the efficacy was maintained for 52 weeks with active rheumatoid arthritis. Ozoralizumab showed an acceptable tolerability profile over 52 weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidHumansMethotrexateTumor Necrosis Factor InhibitorsTreatment OutcomeDrug Therapy, CombinationAntibodies, MonoclonalDouble-Blind Method

Stichwörter der Autor:innen

JapaneseVHH antibodyozoralizumabrheumatoid arthritistumour necrosis factor alpha inhibitor

Substanzen

MethotrexateTumor Necrosis Factor InhibitorsAntirheumatic AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan.
  • Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Keio University School of Medicine, Tokyo, Japan.
  • Saitama Medical University, Saitama, Japan.

ORCID-Profile: Yoshiya Tanaka, Masafumi Kawanishi, Tsutomu Takeuchi

Förderung

  • Taisho Pharmaceutical Co., Ltd.

Zitieren

APA

Tanaka, Y., Kawanishi, M., Nakanishi, M., Yamasaki, H., & Takeuchi, T. (2023). Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). Modern Rheumatology. https://doi.org/10.1093/mr/roac126

Vancouver

Tanaka Y, Kawanishi M, Nakanishi M, Yamasaki H, Takeuchi T. Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). Modern Rheumatology. 2023. doi:10.1093/mr/roac126

BibTeX
@article{Tanaka2023,
  author = {Tanaka, Yoshiya and Kawanishi, Masafumi and Nakanishi, Megumi and Yamasaki, Hironori and Takeuchi, Tsutomu},
  title = {Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac126}
}
Kostenlos starten →